M
Mark A. Sperling
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 170
Citations - 7697
Mark A. Sperling is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Insulin & Glucagon. The author has an hindex of 40, co-authored 167 publications receiving 7032 citations. Previous affiliations of Mark A. Sperling include Beaumont Hospital & University of Cincinnati Academic Health Center.
Papers
More filters
Journal ArticleDOI
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state.
Joseph I. Wolfsdorf,Nicole Glaser,Michael S. D. Agus,Maria Fritsch,Ragnar Hanas,Arleta Rewers,Mark A. Sperling,Ethel Codner +7 more
TL;DR: Recommendations concerning fluid management have been modified to reflect recent findings from a randomized controlled clinical trial showing no difference in cerebral injury in patients rehydrated at different rates with either 0.45% or 0.9% saline.
Journal ArticleDOI
Insulin resistance in short children with intrauterine growth retardation.
Paul L. Hofman,Wayne S. Cutfield,Elizabeth Robinson,Richard N. Bergman,Ram K. Menon,Mark A. Sperling,Peter D. Gluckman +6 more
TL;DR: Short prepubertal IUGR children have a specific impairment in insulin sensitivity compared to their normal birth weight peers, a potential marker for the early identification and intervention in the development of late adult-onset noninsulin-dependent diabetes mellitus.
Journal ArticleDOI
Measurement of “True” Glucose Production Rates in Infancy and Childhood with 6,6-Dideuteroglucose
Dennis M. Bier,Rosemary D. Leake,Morey W. Haymond,Kenneth J. Arnold,Larry D Gruenke,Mark A. Sperling,David M. Kipnis +6 more
TL;DR: The first measurements of “new” glucose production in childhood, measured in 54 infants and children for the first time, suggest that brain size may be a principal determinant of those factors that regulate hepatic glucose output throughout life.
Journal ArticleDOI
Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children
Paul S. Thornton,Charles A. Stanley,Diva D. De León,Deborah L. Harris,Morey W. Haymond,Khalid Hussain,Lynne L. Levitsky,Mohammad Hassan Murad,Paul J. Rozance,Rebecca A. Simmons,Mark A. Sperling,David A. Weinstein,Neil H. White,Joseph I. Wolfsdorf +13 more
TL;DR: Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children.
Journal ArticleDOI
Diabetic Ketoacidosis in Infants, Children, and Adolescents: A consensus statement from the American Diabetes Association
TL;DR: Infants and toddlers in DKA may be misdiagnosed as having pneumonia, reactive airways disease (asthma), or bronchiolitis and therefore treated with glucocorticoids and/or sympathomimetic agents that only compound and exacerbate the metabolic derangements.